XDEMVY
Growthlotilaner ophthalmic solution
NDAOPHTHALMICSOLUTION/DROPS
Approved
Jul 2023
Lifecycle
Growth
Competitive Pressure
0/100
Data completeness
3/8 — Basic
Drug data last refreshed 3d ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
XDEMVY (lotilaner ophthalmic solution) is an ectoparasiticide approved by the FDA on July 24, 2023, for topical ophthalmic use. It represents a novel treatment approach for parasitic infections affecting the eye, delivered as a solution/drops formulation. As a newly approved NDA product, XDEMVY addresses an unmet need in ophthalmic parasitology with a unique mechanism of action within its pharmacologic class.
$0.0BPart D
12.6 years to LOEMechanism of Action
Pharmacologic Class:
Ectoparasiticide
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
XDEMVY's specialty ophthalmic focus creates opportunities for specialized brand managers, medical science liaisons targeting ophthalmology, and field teams with expertise in niche indications. Currently, zero open positions are linked to this product, though roles may expand as the commercial footprint grows. Success requires expertise in parasitic eye diseases and relationships with ophthalmology specialists and infectious disease practitioners.
External Resources
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.